TY - JOUR
T1 - Association between body powder use and ovarian cancer
T2 - The African American Cancer Epidemiology Study (AACES)
AU - Schildkraut, Joellen M.
AU - Abbott, Sarah E.
AU - Alberg, Anthony J.
AU - Bandera, Elisa V.
AU - Barnholtz-Sloan, Jill S.
AU - Bondy, Melissa L.
AU - Cote, Michele L.
AU - Funkhouser, Ellen
AU - Peres, Lauren C.
AU - Peters, Edward S.
AU - Schwartz, Ann G.
AU - Terry, Paul
AU - Crankshaw, Sydnee
AU - Camacho, Fabian
AU - Wang, Frances
AU - Moorman, Patricia G.
N1 - Funding Information:
This work was supported by the NCI (grant number R01CA142081; to J.M. Schildkraut, A.J. Alberg, E.V. Bandera, J. Barnholtz-Sloan, M.L. Bondy, M.L. Cote, E. Funkhouser, E.S. Peters, A.G. Schwartz, P. Terry, and P.G. Moorman). Additional support was provided by the Metropolitan Detroit Cancer Surveillance System with funding from the NCI, NIH, and the Department of Health and Human Services (contract number HHSN261201000028C), and the Epidemiology Research Core, supported in part by the NCI Center (grant number P30CA22453; to A.G. Schwartz and M.L. Cote) to the Karmanos Cancer Institute, Wayne State University School of Medicine. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher Copyright:
©2016 AACR.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Background: Epidemiologic studies indicate increased ovarian cancer risk among women who use genital powder, but this has not been thoroughly investigated in African American (AA) women, a group with a high prevalence of use. We evaluate the relationship between use of genital powder and nongenital powder in invasive epithelial ovarian cancer (EOC). Methods: Subjects are 584 cases and 745 controls enrolled in the African American Cancer Epidemiology Study (AACES), an ongoing, population-based case-control study of EOC in AA women in 11 geographic locations in the United States. AA controls were frequency matched to cases on residence and age. Logistic regression was used to calculate ORs and 95% confidence intervals (CI) for associations between genital and nongenital powder exposure and EOC risk, controlling for potential confounders. Results: Powder use was common (62.8% of cases and 52.9% of controls). Genital powder was associated with an increased risk of EOC (OR = 1.44; 95% CI, 1.11-1.86) and a dose-response relationship was found for duration of use and number of lifetime applications (P < 0.05). Nongenital use was also associated with EOC risk, particularly among nonserous EOC cases (OR = 2.28; 95% CI, 1.39-3.74). An association between powder use and upper respiratory conditions suggests an enhanced inflammatory response may explain the association between body powder and EOC. Conclusions: In a study of AA women, body powder use was significantly associated with EOC risk. Impact: The results support that body powder is a modifiable risk factor for EOC among AA women.
AB - Background: Epidemiologic studies indicate increased ovarian cancer risk among women who use genital powder, but this has not been thoroughly investigated in African American (AA) women, a group with a high prevalence of use. We evaluate the relationship between use of genital powder and nongenital powder in invasive epithelial ovarian cancer (EOC). Methods: Subjects are 584 cases and 745 controls enrolled in the African American Cancer Epidemiology Study (AACES), an ongoing, population-based case-control study of EOC in AA women in 11 geographic locations in the United States. AA controls were frequency matched to cases on residence and age. Logistic regression was used to calculate ORs and 95% confidence intervals (CI) for associations between genital and nongenital powder exposure and EOC risk, controlling for potential confounders. Results: Powder use was common (62.8% of cases and 52.9% of controls). Genital powder was associated with an increased risk of EOC (OR = 1.44; 95% CI, 1.11-1.86) and a dose-response relationship was found for duration of use and number of lifetime applications (P < 0.05). Nongenital use was also associated with EOC risk, particularly among nonserous EOC cases (OR = 2.28; 95% CI, 1.39-3.74). An association between powder use and upper respiratory conditions suggests an enhanced inflammatory response may explain the association between body powder and EOC. Conclusions: In a study of AA women, body powder use was significantly associated with EOC risk. Impact: The results support that body powder is a modifiable risk factor for EOC among AA women.
UR - http://www.scopus.com/inward/record.url?scp=84990062581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84990062581&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-15-1281
DO - 10.1158/1055-9965.EPI-15-1281
M3 - Article
C2 - 27197282
AN - SCOPUS:84990062581
SN - 1055-9965
VL - 25
SP - 1411
EP - 1417
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 10
ER -